Pfizer ( PFE 1.46%) made a fortune thanks to its work in the COVID-19 market. In 2022, it became the first company in the ...

A colon cancer study highlighted the importance of the National Cancer Institute, while cancer doctors got a look at a ...

Pfizer decided to think bigger and to in-license SSGJ-707 from 3SBio. The deal allows increased ... much lower financial risks than an outright acquisition of a company like Summit.

The acquisition of SSGJ-707 coincides with Pfizer and Summit collaborating on ... stated that no changes are expected when asked how the 3SBio deal would impact its partnership with Summit.

Under the deal, announced on May 20, Pfizer gains the opportunity to develop and sell the SSGJ-707 drug in markets outside of ...

Pfizer has announced a new agreement to develop and market a cancer drug being developed by Chinese drugmaker 3SBio.

U.S. drugmaker Pfizer said it would license an experimental cancer treatment from China's 3SBio Inc , paying $1.25 billion ...

Recently, BioNTech SE announced an $800 million acquisition of Biotheus ... subject to customary regulatory approvals and 3SBio shareholder consent. Upon completion, Pfizer will also make a $100 ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced it has entered into an exclusive global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK), a leading Chinese ...

Pfizer has joined the PD-1xVEGF bispecific gold rush. The Big Pharma is paying 3SBio $1.25 billion upfront for ex-China rights to a clinical candidate, establishing itself as a challenger to ...

Pfizer (NYSE:PFE) has signed an exclusive global licensing deal with China’s 3SBio for the development of its cancer drug candidate, SSGJ-707. SSGJ-707, a bispecific antibody targeting PD-1 and ...